Recent Quotes (30 days)

You have no recent quotes
chg | %

Verisante Technology Inc  

(Public, CVE:VRS)   Watch this stock  
Find more results for CVE:THZ
0.0000 (0.00%)
Nov 27 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.07 - 0.08
52 week 0.05 - 0.14
Open 0.08
Vol / Avg. 139,710.00/125,429.00
Mkt cap 6.87M
P/E     -
Div/yield     -
EPS -0.03
Shares 91.66M
Beta 0.74
Inst. own     -

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -527.87% -1477.66%
Operating margin -497.01% -1537.63%
EBITD margin - -1012.74%
Return on average assets -40.34% -63.67%
Return on average equity -68.30% -81.66%
Employees 8 -
CDP Score - -


140-2639 Viking Way
+1-604-6050507 (Phone)
+1-604-6050508 (Fax)

Website links


Verisante Technology, Inc. is a Canada-based medical device company. The Company's product portfolio includes Verisante Aura, Verisante Core, Multispectral Imaging Camera (MSI), and ClearVu and ClearVu Elite. Verisante Aura is a spectroscopy system designed to aid in the detection of skin cancer. Aura has been approved for sale in Canada, Europe and Australia. Verisante Core uses an endoscopic attachment to aid in the detection of lung, colon, cervical, and other cancers. The MSI device is intended to assist medical professionals in the detection of all major forms of skin cancer. ClearVu and ClearVu Elite are endoscopy systems for early lung cancer detection. The ClearVu system is a simultaneous white light and fluorescence real time video accessory, which is used with a fiberoptic bronchoscope for lung cancer examinations.

Officers and directors

Thomas A. Braun President, Chief Executive Officer, Chief Business Development Officer, Director
Anna Trinh Chief Financial Officer, Vice President - Administration, Corporate Counsel, Secretary
Joseph Biegel Independent Director
Karen Boodram Independent Director
Age: 49
Christopher John Wesley Dennis Independent Director
Jake J. Thiessen Ph.D. Independent Director
Age: 66